The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Clinical Effectiveness Of Aspirin In Healing Chronic Venous Leg Ulcers: A Randomised Double-blinded Placebo-controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$791,980.00
Summary
Chronic venous leg ulcers (VLU) are a common and costly problem. People with chronic wounds found on the ankles and legs can be spontaneous or occur after minor trauma, they are often painful and ooze fluid. The burden is expected to rise with an ageing population and growing epidemic of diabetes and obesity which will increase challenges for clinicians. We will perform a clinical trial to see if aspirin plus 3 layer compression in people with venous leg ulcers heal more quickly.
Identification Of Early Predictors Of Non-healing Venous Leg Ulcers And Development Of A Risk Assessment Tool
Funder
National Health and Medical Research Council
Funding Amount
$43,271.00
Summary
Venous leg ulcers make up about 70% of all chronic leg ulcers and are often debilitating. This project aims to examine the relationships between physiological and psychosocial variables in patients with chronic venous leg ulcers in relation to healing at 24 weeks thereby guiding the development of a risk assessment tool that will then be tested. Identification of risk factors for non-healing at 24 weeks would offer an opportunity for clinicians to be able to determine realistic outcomes.